朴素的思枫
Lv3
395 积分
2023-05-11 加入
-
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
18天前
已完结
-
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
18天前
已关闭
-
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
20天前
已完结
-
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
1个月前
已完结
-
Computational Identification of Preneoplastic Cells Displaying High Stemness and Risk of Cancer Progression
4个月前
已完结
-
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
4个月前
已完结
-
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
5个月前
已完结
-
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
5个月前
已完结
-
Hepatocellular carcinoma
5个月前
已完结
-
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
11个月前
已完结